Clinical proof of concept of PDMSD product (v.1.0)

  • Research type

    Research Study

  • Full title

    Clinical proof of concept and commercial PDMSD product development

  • IRAS ID

    182913

  • Contact name

    Nishal Govindji-Bhatt

  • Contact email

    nishal.govindji-bhatt@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Duration of Study in the UK

    1 years, 4 months, 28 days

  • Research summary

    The Peritoneal Device Microbial Sensing Device (PDMSD) is a point-of-care device able to signal the presence of clinically relevant levels of infection in waste peritoneal dialysis fluid through simple colour changes in a readout window. PDMSDs would act as an early warning system for peritonitis, replacing the current ambiguity and risk-prone self-monitoring of effluent cloudiness by patients. This will signal an emerging infection at an earlier stage than is currently possible. We believe that PDMSDs have the potential to improve outcomes for patients and extend the useful lifespan of PD therapy, which must often be abandoned due to recurrent infection problems. 100 ex vivo effluent samples from 10-50 patients will be required for this phase of the research, which will be tested with the PDMSD in vitro to provide the first clinical validation for the PDMSD and supporting safety of the device (specifically demonstrating the device does not produce false negatives or false positives with real clinical effluent).

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    15/NW/0641

  • Date of REC Opinion

    1 Oct 2015

  • REC opinion

    Further Information Favourable Opinion